Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS

NCT00202995 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

91

Enrollment

INDUSTRY

Sponsor class

Stopped Slow enrollment decreased sample size No unexpected safety issues.

Conditions

Relapsing Remitting Multiple Sclerosis

Interventions

DRUG: Glatiramer Acetate
DRUG: Betaseron
DRUG: Rebif

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.